Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says

Executive Summary

Center for Drug Evaluation and Research Director says rare disease reviews need multiple specialists, which likely would not fit into a centralized rare disease review group.
Advertisement

Related Content

US FDA's Streamlined Hiring Pilot Restarts After Delay
US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier
US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
US FDA May Create Immunology, Neuroscience Centers Of Excellence
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
FDA Says Goodbye To Its Antiviral Drugs Advisory Committee
FDA DRUG ADVISORY COMMITTEES SHOULD NOT BE DISMANTLED, NDMA URGES

Topics

Advertisement
UsernamePublicRestriction

Register

PS123867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel